| Main Subject |
Hubs | Hubbers | Topics | Request |
| #1 in Business | Subscribe Email Print |
|
You are here: Home > Business > Management > Innovation Management - Eliciting Dominant Ideas |
|
Main Subject - Innovation Management - Eliciting Dominant Ideas
Creativity can be defined as problem identification and idea generation whilst innovation can be defined as idea sel According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product ection, development and commercialisation. There are other useful definitions in this field, for example, creativit ; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug. Examples of combination products may in can be defined as consisting of a number of ideas, a number of diverse ideas and a number of novel ideas. There ar lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together. distinct processes that enhance problem identification and idea generation and, similarly, distinct processes that here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe nhance idea selection, development and commercialisation. Whilst there is no sure fire route to commercial success, d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations. Combination pro hese processes improve the probability that good ideas will be generated and selected and that investment in develop ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc ng and commercialising those ideas will not be wasted. eliciting Dominant Ideas One of the most useful me easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi thods of generating ideas is to elicit the dominant ideas or assumptions of an endeavour. Each dominant idea in turn nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically then acts as the root to a pathway from which other ideas can be elicited. This is akin to creating a custom framewo and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ k for the task. For example, Ferrari may not be selling enough cars and the sales team may “brainstorm” to discover ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi why? Individual managers will identify varying problems, such as: the price is too high, the price is too low, the ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it. Following aspects would a olour is wrong, the marketing is flawed etc. Each of these is in itself a pathway to idea generation. Moving slight dd to the challenges in developing combination products: Which markets to tap where the combination products can do fairly well? Which combination prod y higher, they may ask why clients are buying their cars at all. And answers could include: demonstrate wealth, pick cts are meaningful and rational? Which therapeutic categories to select? Which Combinations can address unmet needs of the patients? Do combin up chicks, demonstrate success etc. Again, these are pathways to different ideas. Then the managers may move onto h tions increase the patient compliance? What would be the developing cost? How to tackle the risks encountered during combination product developmen igher concepts. Why are the clients buying their cars: to raise their status. What other value adding options help t t? As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel raise the client’s status. These and other topics are covered in depth in the MBA dissertation on Managing Creativ ping new procedures for reviewing their safety, efficacy and quality. Professional from academic institutions, pharmaceutical industries, health care indust ty & Innovation, which can be purchased (along with a Creativity and Innovation DIY Audit, Good Idea Generator Softw y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products re and Power Point Presentation) from http://www.managin . As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de -creativity.com/ You can also receive a regular, free newsletter by entering your email address at this site. elopment. They need to be wiser in analyzing the market trends and the regulatory requirements. Companies that provide selfless information through particip ou are free to reproduce this article as long as no changes are made and the author's name and site URL are retained tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
Related Articles:3 Keys to Managing Career Burnout Quiz - What Kind of Entrepreneur Are You? Marketing and Promoting in the Franchising Industry
|